BMY vs. TECH: Bristol-Myers Squibb vs. Bio-Techne Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bristol-Myers Squibb (BMY) at 44.01% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Bristol-Myers Squibb (BMY) at 18.47% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.

Bristol-Myers Squibb (BMY) at 33.79% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bristol-Myers Squibb (BMY) at -0.22% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Bio-Techne (TECH) reports EPS growth of 152.17%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Bristol-Myers Squibb (BMY) at 1.59 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Bio-Techne (TECH) at 0.13 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Both Bristol-Myers Squibb (BMY) at 3.99% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Bristol-Myers Squibb (BMY) at 55.88% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Bristol-Myers Squibb (BMY) at 13.78 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Bio-Techne (TECH) at 9.31 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Bristol-Myers Squibb (BMY) at 5.43 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics